Incorporated in 2001, Sai Parenterals Ltd. is a vertically integrated pharmaceutical company specializing in complex formulations and high-value manufacturing. The firm operates a balanced dual-model strategy, split between Branded Generic Formulations and a high-growth Contract Development and Manufacturing Organization (CDMO) segment. With a therapeutic footprint spanning cardiovascular, neuropsychiatry, and critical care antibiotics, the company distinguishes itself through specialized capabilities in sterile injectables and diverse dosage forms.

Strategically, the company is pivoting toward global scale. By leveraging five manufacturing facilities in India—holding prestigious TGA-Australia and WHO-GMP accreditations—it has successfully expanded into regulated markets. The November 2025 acquisition of a majority stake in Noumed Pharmaceuticals marks a significant milestone, providing Sai Parenterals with an established distribution platform and government tender access in Australia and New Zealand. This integration of low-cost, high-compliance Indian manufacturing with direct international retail access positions the company as a competitive, mid-tier global pharmaceutical player.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

*Market cap @upper band

• Diversified generic formulations player with an established track record
• Strategically located and accredited Manufacturing Facilities
• Strong focus on CDMO business
• Well-established sales network in India and overseas
• Track record of value-accretive acquisitions
• Experienced Promoters and Senior Management with extensive domain knowledge.

The Company SAI PARENTERALS LIMITED IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Capacity expansion and upgradation of manufacturing facilities
• Establishment of a new R&D Centre
• Repayment/prepayment of certain outstanding borrowings
• Working capital requirements
• Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
• General corporate purposes.

At the upper band of IPO Rs. 392, the stock is valued at 119.88 P/E multiple. Hence, well-informed investors would wait before subscribing for medium to long term perspective.